Does the FDA’s MedWatch accept reports about cannabis and cannabinoid-based medicines?
In the January 2020 NEJM, a letter to the editor clarifies a statement made in a Sept 2019 NEJM letter to the editor. The January 2020 letter entitled ” Reporting Adverse Events for Cannabis to the FDA” includes the following statement: “Consumers and health care professionals can directly report to the FDA MedWatch program adverse events and other problems, such as product quality issues or medication errors, that they believe are associated with medical products. Although the majority of reports received are for FDA-approved products, reports regarding unapproved products, including cannabis and cannabis-derived products, are accepted through this pathway. The FDA has received reports of adverse events in patients using cannabis or cannabis-derived products to treat medical conditions and recreationally.”